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INTRODUCTION
Chordoma is an extremely rare cancer, with an incidence of about one case per million persons per year in the USA (about 300 cases per year) [1] . Chordoma has been called ''bone cancer'' [2] , but this designation is debatable based on histologic features, which are more consistent with its presumed tumor of origin, namely, the residual embryonic notochord tissue [3, 4] .
Designating chordoma as a ''bone tumor'' appears to be a holdover from the initial description of the disease by Virchow [5] , but it was called into question soon thereafter by Ribbert [6] , who coined the name ''chordoma'' based on its similarity to notochord tissue [7] .
The relationship of chordoma to the notochord was strengthened by the finding that brachyury, a transcription factor found in notochord tissue and essential for embryonic development, is overexpressed in chordoma [3, 8] . Regardless of its historical designation, chordoma has unique histologic, radiographic, and clinical characteristics that call for chordoma-specific research to improve outcomes for patients with the disease. In this review, I briefly review the previously published natural history of the disease, including tumor characteristics, standard treatment paradigms, clinical management issues, and results of systemic treatment trials to date, to provide context for potential therapeutic targets and possible future treatment options.
EPIDEMIOLOGY, PRESENTATION, AND DIAGNOSIS
Chordoma is most commonly diagnosed between ages 50 and 60, and it is more common in men than women, and rare in children [1] . Primary tumors develop along the axial spine, with approximately one-third of cases presenting in the clivus, mobile spine, and sacrum, respectively [1] . Disease presentation depends on tumor location and is related to the structures near which the tumor is growing. For example, patients with clival chordomas may present with headache, diplopia, or impairment of other cranial nerves, while those with sacral chordomas may present with low back or buttocks pain, neuropathy, and/or gait disturbance [7] . Patients may be diagnosed with large tumor masses in the sacrum due to the slow-growing nature of the disease, non-specific symptom profile, and a relatively large space for tumors to occupy before causing significant focal symptoms. Imaging findings that would point to chordoma include a mass along the axial spine, likely invading surrounding bone, which has a similar intensity to surrounding tissue on T1-weighted images, but appears hyperintense on T2-weighted images [9, 10] . Unfortunately, due to the slow-growing nature of chordoma, which results in insidious, non-specific symptoms, diagnosis may be delayed for months or years. The median overall survival (OS) from time of diagnosis has been estimated at around 6 to 7 years [1] , but the range of outcomes is very wide and may be related to prognostic markers, including treatment options at the time of diagnosis [11] [12] [13] , as detailed below. After surgical resection or initial biopsy, the diagnosis of chordoma is confirmed based on the classical (conventional) appearance of ''sheets and cords of round to polygonal'' tumor cells filled with occasionally large mucin-filled eosinophilic cytoplasm called physaliphorous cells [14] . Two less common chordoma variants are chondroid chordoma and dedifferentiated chordoma. Features of chondroid chordoma include the presence of ''cartilaginous differentiation, not present in classical chordoma'' [14] . Dedifferentiated chordoma occurs in a small subset of patients (\5%); it has an aggressive course and its features are consistent with those of spindle cell (sarcomatoid) carcinoma under histologic review [15, 16] . In cases where the diagnosis is not clear, staining for nuclear expression of brachyury distinguishes chordoma from tumors with similar morphologic features [8, 17, 18] .
TREATMENT AND INITIAL PROGNOSIS
In 2015, the Chordoma Foundation and its advisors published a global consensus based on the input of world experts from the fields of medical oncology, radiation oncology, neurosurgery, and orthopedic surgery during the 2013 European Society for Medical Oncology annual meeting [19] . Practicing clinicians should use these guidelines when initially seeing a patient with chordoma, but the importance of patients being seen by a dedicated multidisciplinary team with experience in this rare disease cannot be overstated.
Surgery is the mainstay of treatment for primary and/or recurrent chordoma when feasible, and the outcome of surgery is closely related to the expected outcome for a given patient. Surgical techniques are specific to tumor site, but in general, the goal is to achieve a local excision with clear margins.
The surgical management of chordoma has been discussed in detail in other recent reviews [2, 7, 20 ] and thus will not be a focus of this review. However, multiple retrospective analyses have demonstrated the impact of surgery on prognosis [21] [22] [23] . In clival chordoma, though, there is evidence that aggressive resection may actually be the more cautious approach [13] because wide local excision is commonly not an option [22] .
Radiotherapy also plays a key role in the management of patients with localized chordoma, particularly in the adjuvant setting after full resection or subtotal resection and as the primary treatment in unresectable disease.
One series from Choy et al. indicated that the use of adjuvant radiotherapy was the most important variable influencing time to progression [13] . A research group from Massachusetts General Hospital demonstrated excellent disease control with adjuvant high-dose radiotherapy after surgery in primary tumors after resection, but poor outcomes in recurrent disease [12] . This group went on to show reasonable tumor control with high-dose proton or photon radiotherapy in patients with primary, unresected chordoma, with 5-year OS and local progression-free survival (PFS) of 78.1% and 79.8%, respectively [24] . The same group demonstrated very low recurrence rates in patients with localized spinal chordoma treated with high-dose radiotherapy, with the exception of locally recurrent chordomas, which had a 5-year recurrence rate of 50% [25] . Because proton-beam therapy is capable of delivering high doses of radiotherapy to focal targets, it has advantages over photon therapy. However, it is not clear that, at equivalent doses, proton therapy has any advantage over photon therapy in terms of disease control or the likelihood of symptom control.
Surgery, when feasible, should aim for margin-negative resection without penetration of the capsule, with adjuvant high-dose radiotherapy for optimal local tumor control [19] . Because this outcome is not possible for most patients, prediction of clinical outcome is very difficult for a given patient at the time of initial management. Patients with residual disease after surgery or unresectable disease at the time of diagnosis should consider high-dose radiotherapy at a center with expertise in delivering such doses for chordoma. An important surgical aspect of the tumor is related to its histology. These tumors contain gelatinous material that can spill into the resection cavity even with careful planning, and recurrence often occurs at the margins of the resected tumor. [22, 27] (Fig. 1) . Because some sites of metastatic chordoma may not be well visualized by an imaging modality that can easily detect other sites of metastasis ( Fig. 1) , or because clinical evaluation commonly focuses on local recurrence, sites of metastatic disease can easily be missed. However, this may not be an issue of great significance in most cases because local recurrence is still the major cause of morbidity and mortality [22] . In older series, OS in patients with metastatic disease has been reported as approximately 1 year [28] , but more recent series have indicated a median OS closer to 3 years [22, 29] . This apparent shift in survival from the time of detection of metastatic disease may be due to detection bias, in which metastatic lesions are identified earlier with improved imaging modalities and more thorough evaluation. Alternatively, the difference could be due to improved treatment methods over time.
SYSTEMIC TREATMENT
To date, there has been no randomized, controlled trial of a therapeutic agent in locally advanced and/or metastatic chordoma. Perhaps owing to the lack of clear historical control data in this population, there also has not been a study that has clearly defined b Fig. 1 objective radiographic response, and the median PFS was 9.9 months [43] . Thalidomide has also been reported to induce a radiographic response in one case report [44] . Despite 
POTENTIAL FUTURE TREATMENTS

Brachyury
In addition to being a diagnostic marker for chordoma, brachyury may be a potential target for treatment [46, 47] . Brachyury appears to be an oncogenic driver of chordoma [3, 48] . The non-synonymous presence of the rs2305086 single nucleotide polymorphism was associated with increased risk of chordoma in one series [49] , yet in another study, in Chinese patients, no such association was found [50] .
It was previously thought that brachyury was specific only to chordoma and could be used, primarily, as a diagnostic tool [8, 51] [56] .
In epithelial tumors, brachyury expression drives epithelial-to-mesenchymal transition, inducing stem-like features such as migration, invasiveness, and resistance to conventional therapy [57] [58] [59] . In retrospective analyses of cohorts of patients with prostate [52] , colorectal [53] , breast [54] , lung [55] , and hepatocellular carcinoma [34] , brachyury expression has been associated with poor prognosis. Interestingly, chordoma cells express many of the markers of mesenchymal cells typically induced with brachyury upregulation in other tumor types, including decreased e-cadherin levels and increased n-cadherin [60] and vimentin levels [61] .
Historically, transcription factors have been considered ''undruggable'' [62] with targeted or standard cytotoxic agents, but other potential avenues for targeting brachyury have been proposed, including small inhibitory RNA, epigenetic modulation, and immune-based therapy [63, 64] . To date, the only attempts to target brachyury have been with two therapeutic cancer vaccines. Our group recently completed a phase I trial of GI-6301
(recombinant yeast-brachyury vaccine) which enrolled 11 patients with advanced chordoma (NCT01519817) [65] . One patient had a confirmed radiographic partial response (PR) by the RECIST guideline, and a second had a mixed response; the median PFS in the chordoma group was 8.3 months. The vaccine induced brachyury-specific T cell responses in both the majority of all patients enrolled and the subset of patients enrolled with chordoma.
There were no significant toxicities related to the vaccine [65] . Notably, the two patients with evidence of tumor shrinkage both had radiotherapy within 3.5 months of being enrolled on study. Given the low likelihood of radiographic response with radiotherapy alone in the advanced disease setting, our hypothesis was an immunomodulatory effect of radiotherapy on chordoma cells which resulted in an increased responsiveness to T cell-mediated killing. Hodge et al. described a similar effect in other tumor cell lines [66] [67] [68] .
Another phase I study of a vaccine targeting brachyury has recently completed accrual (NCT02179515). This vaccine is composed of a modified vaccinia virus Ankara (MVA) vector containing the transgene for brachyury and three costimulatory molecules (designated TRICOM). [61] . Both of these targets can also be targeted immunologically with therapeutic cancer vaccines [69, 70] and may be candidates for future clinical trials.
Mucin 1 and Carcinoembryonic Antigen
Survivin
Survivin is another protein associated with poor prognosis and metastatic potential in other tumor types [71] [72] [73] [74] [75] [76] . It is a member of the inhibitor of apoptosis (IAP) gene family. Similar to brachyury, it is rarely or never expressed in normal adult tissue, but it is found in many tumor cell types, including lung, colon, breast, prostate, and pancreatic cancer cells [77] which has been demonstrated to be safe in other diseases [80] [81] [82] , could be a potential therapeutic agent for use in chordoma [79] . and went on to demonstrate that transfection of cell lines with miRNA-1 could suppress Met expression and decrease chordoma cell proliferation in vitro, leading them to suggest that miRNA-1 could be a candidate for therapeutic intervention in the future [84] . Later work by the same group confirmed that miRNA-1 is downregulated in 93.7% of chordoma tissues and has an inverse correlation with Met expression [85] , which appears to occur downstream through control of the Slug gene in chordoma cells [86] .
MicroRNA-Focused Approaches
In a similar study, Long et al. evaluated the differential expression of miRNA and mRNA in chordoma versus notochord tissues [87] . Their microarray analysis identified differential expression of 33 miRNAs and 2791 mRNAs.
Interestingly, 911 mRNAs were connected to signaling pathways regulated by miRNAs. These Further work by other groups has identified a number of potentially important differential expression patterns of miRNA in chordoma relative to normal tissue. These include mRNA-31, which has an apoptotic effect on chordoma cells by downregulating the expression of c-MET and radixin [88] , miRNA-608 and miRNA-34a, which regulate EGFR, MET, and Bcl-xL [89] , miRNA-10a and miRNA-125a, which were associated with adenosine deaminase acting on RNA expression [90] , and miRNA-140-3p [91] , miRNA-155 [92] , and miRNA-1237-3p [93] Unfortunately, despite rational selection of agents based on potential therapeutic targets identified by extensive preclinical work, radiographic response rates have been very low.
Thus, the impact of these agents cannot be fully assessed, which has precluded their approval for use in advanced chordoma by the FDA or other regulatory agencies. Additional therapeutic targets continue to emerge, including brachyury, survivin, and others not described here. The recent activity seen in other tumor types treated with immunotherapy suggests that therapeutic cancer vaccines, immune checkpoint inhibitors, or a combination of these agents may be potential therapeutic options for chordoma. Careful selection of patient populations and endpoints will be required to definitively demonstrate efficacy and increase the armamentarium for physicians treating this rare tumor.
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